• Giuseppe TridenteEmail author


Abatacept (Orencia®, Brystol-Meyers Squibb) is a soluble fusion protein binding to CD80 and CD86, thus blocking their interaction with CD28 receptor and the consequent costimulatory signal to activate T lymphocytes.


Rheumatoid Arthritis Rheumatoid Arthritis Patient Juvenile Idiopathic Arthritis Herpes Zoster Juvenile Idiopathic Arthritis Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_41_MOESM1_ESM.xls (68 kb)
Supplementary material 1 (XLS 70 kb)


  1. 1.
    Abatacept (Orencia®) BLA125118 Medical Review FDA, Dec 2005Google Scholar
  2. 2.
    Abatacept (Orencia®) WC500048938 Scientific Discussion EMEA, June 2007Google Scholar
  3. 3.
    Abatacept (Orencia®) WC500095025 Scientific Discussion EMEA, July 2010Google Scholar
  4. 4.
    Abatacept (Orencia®) Prescribing Information BMS, Dec 2011Google Scholar
  5. 5.
    Abatacept (Orencia®) WC500135471 CHMP Assessment Report EMEA, Nov 2012Google Scholar
  6. 6.
    Xu Z, Juan V, Ivanov A et al (2012) Affinity and cross-reactivity engeenering of CTLA4-Ig to modulate T cell costimulation. J Immunol 189:4470–4477PubMedCrossRefGoogle Scholar
  7. 7.
    Herrero-Beaumont G, Martinez-Calatrava MJ, Castañeda S (2012) Mecanismo de acción de abatacept: concordancia con su perfil clinico. Reumatol Clin 8:78–83Google Scholar
  8. 8.
    Bonelli M, Ferner E, Göschl L et al (2013) Abatacept (CTLA4-Ig) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum. doi: 10.1002/art.37787 (accepted article)
  9. 9.
    Keystone EC, Kremer JM, Russell A et al (2012) Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis 71:857–861PubMedCrossRefGoogle Scholar
  10. 10.
    Schiff M, Pritchard C, Huffstutter JE et al (2009) The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 68:1708–1714PubMedCrossRefGoogle Scholar
  11. 11.
    Matsubara T, Yamana S, Tohma S et al (2012) Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. Mod Rheumatol. doi: 10.1007/s10165-012-0722-x Google Scholar
  12. 12.
    Kaine J, Gladstein G, Strusberg I et al (2012) Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (Phase IIIb ALLOW study). Ann Rheum Dis 71:38–44PubMedCrossRefGoogle Scholar
  13. 13.
    Takeuchi T, Matsubara T, Nitobe T et al (2012) Phase II dose−response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol. doi: 10.1007/s10165-012-0668-z Google Scholar
  14. 14.
    Westhovens R, Robles M, Ximenes AC et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68:1870–1877PubMedCrossRefGoogle Scholar
  15. 15.
    Emery P, Durez P, Dougados M et al (2010) Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69:510–516PubMedCrossRefGoogle Scholar
  16. 16.
    Genovese MC, Schiff M, Luggen M et al (2012) Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 39:1546–1554PubMedCrossRefGoogle Scholar
  17. 17.
    Schiff M (2011) Abatacept treatment for rheumatoid arthritis. Rheumatology 50:437–449PubMedCrossRefGoogle Scholar
  18. 18.
    Weinblatt ME, Schiff M, Valente R et al (2013) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis. Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 65:28–38PubMedCrossRefGoogle Scholar
  19. 19.
    Kim PS, Ho GY, Prete PE et al (2012) Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res 64:1265–1268Google Scholar
  20. 20.
    Germanidis G, Hytiroglou P, Zakalka M (2012) Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 56:1420–1429PubMedCrossRefGoogle Scholar
  21. 21.
    Goldzweig O, Hashkes PJ (2011) Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. Drug Des Devel Ther 5:61–70PubMedGoogle Scholar
  22. 22.
    Ruperto N, Lovell DJ, Quartier P et al (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62:1792–1802PubMedCrossRefGoogle Scholar
  23. 23.
    Zulian F, Balzarin M, Falcini F et al (20120) Abatacept for severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 62:821−825Google Scholar
  24. 24.
    Merrill JT, Burgos-Vargas R, Westhovens R et al (2010) The efficacy and safety of abatacept in patients with non-life threatening manifestations of systemic lupus erythematosus. Arthr Rheum 62:3077–3087CrossRefGoogle Scholar
  25. 25.
    Sandborn WJ, Colombel J-F, Sands BE (2012) Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 143:62–69PubMedCrossRefGoogle Scholar
  26. 26.
    Song I-H, Heldmann F, Rudwaleit M et al (2011) Treatment of active ankylosing spondylitis with abatacept: an open-label, 24 week pilot study. Ann Rheum Dis 70:1108–1110PubMedCrossRefGoogle Scholar
  27. 27.
    Lepka FK, Farrenq V, Canouï-Poitrine F et al (2012) Lack of efficacy of abatacept in axial spondyloarthropathies refractory to tumor-necrosis-factor inhibition. Jt Bone Spine 79:47–50CrossRefGoogle Scholar
  28. 28.
    Mease P, Genovese MC, Gladstein G (2011) Abatacept in the treatment of patients with psoriatic arthritis. Results of a six-month, multicenter, randomized, double blind, placebo-controlled, phase II trial. Arthr Rheum 63:939–948CrossRefGoogle Scholar
  29. 29.
    Florent A, Albert C, Giacchero D et al (2010) Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathies. Jt Bone Spine 77:616–627CrossRefGoogle Scholar
  30. 30.
    Elhai M, Meunier M, Matucci-Cerinic M et al (2012) Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-202657 Google Scholar
  31. 31.
    Orban T, Bundy B, Becker D et al (2011) Co-stimulation with abatacept in patients with recent-onset Type 1 diabetes: a randomized, double blind, placebo-controlled trial. Lancet 378:412–419PubMedCrossRefGoogle Scholar
  32. 32.
    Pham T, Bachelez H, Berthelot JM et al (2012) Abatacept therapy and safety management. Jt Bone Spine 79(s1):3−84Google Scholar
  33. 33.
    Oieda-Uribe M, Afif N, Dahan E et al (2013) Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheunatol. doi: 10.1007/s10067-012-2156-4 Google Scholar
  34. 34.
    Molloy ES (2011) PML and rheumatology: the contribution of the disease and drugs. Cleveland Clin J Med 78:s28–s32CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations